

# Silvia Antolin Novoa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2447174/publications.pdf>

Version: 2024-02-01

29  
papers

935  
citations

516215

16  
h-index

454577

30  
g-index

34  
all docs

34  
docs citations

34  
times ranked

1999  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2213-2221.	0.4	168
2	Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy. <i>Oncotarget</i> , 2018, 9, 26406-26416.	0.8	136
3	Circulating miR-200c and miR-141 and outcomes in patients with breast cancer. <i>BMC Cancer</i> , 2015, 15, 297.	1.1	72
4	Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 143, 507-515.	1.1	60
5	Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study. <i>PLoS ONE</i> , 2015, 10, e0126096.	1.1	56
6	Multicenter Phase II Study of Lurbinectedin in <i>BRCA</i> -Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3134-3143.	0.8	43
7	Physical activity and breast cancer risk by pathological subtype. <i>Gynecologic Oncology</i> , 2017, 144, 577-585.	0.6	34
8	Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 693-701.	1.1	34
9	A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothed or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study. <i>Investigational New Drugs</i> , 2019, 37, 98-108.	1.2	33
10	NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 133.	2.2	30
11	Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern Similarity. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2016, 116, 1914-1924.e6.	0.4	26
12	Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer. <i>Cancer</i> , 2012, 118, 241-247.	2.0	25
13	A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study. <i>Oncotarget</i> , 2017, 8, 73144-73153.	0.8	24
14	Overeating, caloric restriction and breast cancer risk by pathological subtype: the EPIGEICAM study. <i>Scientific Reports</i> , 2019, 9, 3904.	1.6	23
15	Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2 <sup>-</sup> ) early breast cancer (EBC): results from the GEICAM/2006-10 study. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 115-125.	1.1	20
16	Diagnostic accuracy of small breast epithelial mucin mRNA as a marker for bone marrow micrometastasis in breast cancer: a pilot study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 1185-1195.	1.2	18
17	Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. <i>European Journal of Cancer</i> , 2019, 120, 54-64.	1.3	18
18	Trajectories of alcohol consumption during life and the risk of developing breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1168-1176.	2.9	17

#	ARTICLE	IF	CITATIONS
19	Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 958-967.	0.7	15
20	Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. <i>Oncologist</i> , 2017, 22, 1301-1308.	1.9	13
21	Serum Phospholipids Fatty Acids and Breast Cancer Risk by Pathological Subtype. <i>Nutrients</i> , 2020, 12, 3132.	1.7	11
22	Primary breast cancer and health related quality of life in Spanish women: The EpiGEICAM case-control study. <i>Scientific Reports</i> , 2020, 10, 7741.	1.6	9
23	Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 853-857.	1.4	9
24	Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution. <i>Breast Cancer: Targets and Therapy</i> , 2018, Volume 11, 29-42.	1.0	6
25	Angiosarcoma radioinducido de mama en paciente con sÃndrome de Li-Fraumeni. <i>CirugÃa EspaÃ±ola</i> , 2019, 97, 114-116.	0.1	4
26	Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine. <i>Clinical and Translational Oncology</i> , 2010, 12, 450-452.	1.2	3
27	A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: results from a phase II study. <i>Clinical and Translational Oncology</i> , 2011, 13, 686-691.	1.2	3
28	Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study. <i>European Journal of Clinical Nutrition</i> , 2022, 76, 1343-1346.	1.3	3
29	Genomic alterations driving breast cancer (BC) metastases and their relationship with the subtype switch in the GEICAM ConvertHER study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1017-1017.	0.8	2